Journal
BLOOD CANCER JOURNAL
Volume 11, Issue 5, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41408-021-00480-w
Keywords
-
Categories
Funding
- Black Swan Research Initiative by the International Myeloma Foundation
- Icelandic Centre for Research [173857]
- European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [716677]
- University of Iceland
- Landspitali University Hospital
- Icelandic Cancer Society
- European Research Council (ERC) [716677] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
The iStopMM study in Iceland is the first population-based screening study for MGUS, including a randomized trial of follow-up strategies. With a high participation rate, the study aims to answer important questions about MGUS and could potentially lead to a paradigm shift towards screening and early therapy in MM.
Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population-based screening study for MGUS including a randomized trial of follow-up strategies. Icelandic residents born before 1976 were offered participation. Blood samples are collected alongside blood sampling in the Icelandic healthcare system. Participants with MGUS are randomized to three study arms. Arm 1 is not contacted, arm 2 follows current guidelines, and arm 3 follows a more intensive strategy. Participants who progress are offered early treatment. Samples are collected longitudinally from arms 2 and 3 for the study biobank. All participants repeatedly answer questionnaires on various exposures and outcomes including quality of life and psychiatric health. National registries on health are cross-linked to all participants. Of the 148,704 individuals in the target population, 80 759 (54.3%) provided informed consent for participation. With a very high participation rate, the data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of screening. The study can lead to a paradigm shift in MM therapy towards screening and early therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available